about
Ridinilazole: a novel therapy for Clostridium difficile infectionIdentification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tubercularsImaging-based chemical screens using normal and glioma-derived neural stem cells.Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.In vivo assessment of SMT19969 in a hamster model of clostridium difficile infection.A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile.Diastereoselective synthesis of quaternary alpha-amino acids from diketopiperazine templates.Automated large-scale culture and medium-throughput chemical screen for modulators of proliferation and viability of human induced pluripotent stem cell-derived neuroepithelial-like stem cells.Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy.Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficileSMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents.SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut modelSynthesis and in vitro evaluation of novel small molecule inhibitors of bacterial arylamine N-acetyltransferases (NATs).Asymmetric synthesis of substituted 1-aminocyclopropane-1-carboxylic acids via diketopiperazine methodology.Asymmetric synthesis and applications of beta-amino Weinreb amides: asymmetric synthesis of (S)-coniine.Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycinDiscovery and SAR of 2-arylbenzotriazoles and 2-arylindazoles as potential treatments for Duchenne muscular dystrophyAntimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycinCombating resistance while maintaining innovation: the future of antimicrobial stewardship
P50
Q26747248-FDF5B516-3F28-440A-A7B7-1CEBA1C804F6Q28833704-3E4FA53F-F764-4685-822B-2D836F672E23Q33640633-1DFB5AD8-51E5-4B80-87AB-52233350EF80Q33831557-2BCE4DBC-B980-4870-B317-61DA42A3063AQ34299171-BE68D3D8-2BBA-4B85-BFEA-CBF6984FDC85Q35146382-AE744D5B-BE46-4DD3-B55C-4DD5BBB5CA57Q35997593-12868069-9D0B-446D-8280-95177BB4C760Q39098199-35D712BA-91A7-4BAB-91A4-AF076F5E7DD5Q39264623-D88E86E6-BB12-4495-8522-8E21AD3C854DQ39566455-B0F71FA2-E4A3-4821-9327-500DA8259B6EQ40916483-18B8DB59-961C-4F53-8025-FBDFD2E37BE7Q41148829-6607F9C2-1FF9-48D7-8CBC-8AB1FFC824EBQ41148853-056D427F-BEF9-4EAE-BDB6-C3372BC4874CQ41629299-0AC7A0D5-F228-473C-A5D7-BCCA5CBB6651Q41752763-4670E241-C126-4C70-8F43-4D7D531CD4B4Q44508038-353CE9D7-0B0B-4F4C-9C43-1BE4969E7B8FQ44573756-A13D4474-4787-47FA-BC8C-EEB033770C54Q53723746-87FDDFFA-7F4C-404F-92E7-8341A085BC20Q58803847-BB0DF104-3B2E-4F6A-A1F1-B4717367953EQ84528057-31A64BF6-9508-4AF0-A5F1-7983ACDA5BE6Q88541439-6E2E4CF6-DC7D-4889-8743-194B8607485FQ90127860-EA9D8DA2-C050-4EF9-B8E3-9CFA60C5447C
P50
description
researcher ORCID ID = 0000-0001-9937-6953
@en
wetenschapper
@nl
name
Richard J Vickers
@ast
Richard J Vickers
@en
Richard J Vickers
@es
Richard J Vickers
@nl
type
label
Richard J Vickers
@ast
Richard J Vickers
@en
Richard J Vickers
@es
Richard J Vickers
@nl
prefLabel
Richard J Vickers
@ast
Richard J Vickers
@en
Richard J Vickers
@es
Richard J Vickers
@nl
P1153
56365982700
P21
P31
P496
0000-0001-9937-6953